2TG Stock Chart & Stats
€202.20
€3.00(1.48%)
At close: 4:00 PM EDT
€202.20
€3.00(1.48%)
Day’s Range― - ―
52-Week Range€170.40 - €236.00
Previous CloseN/A
Volume80.00
Average Volume (3M)2.00
Market Cap
€19.29B
Enterprise Value€23.42K
Total Cash (Recent Filing)€439.60M
Total Debt (Recent Filing)€2.09B
Price to Earnings (P/E)28.7
Beta0.24
Next Earnings
Aug 05, 2026EPS Estimate
2.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.95
Shares Outstanding97,457,680
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)3.02
Price to Sales (P/S)3.66
P/FCF Ratio22.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€247.30Price Target Upside22.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)9.81
Revenue Forecast (FY)€5.59B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA materially lower leverage profile and rising equity provide durable financial flexibility: supports sustained capex, tuck‑in M&A, multi-year buybacks and dividend growth, and increases resilience to macro shocks. Low structural leverage reduces refinancing and interest-rate risks over 2–6 months.
Recurring Consumables And ServicesA business model weighted to consumables, maintenance and outsourced services creates high-repeat revenue and visibility. Installed-equipment affinity products and multi-year service contracts produce predictable cashflows, high customer stickiness, and margin durability versus one-time equipment sales.
Strong Cash Generation / Free Cash FlowConsistent, large free cash flow enables sustained reinvestment and shareholder returns while funding strategic projects. Multi-hundred-million FCF cushions working-capital swings, supports the $1B buyback plan and capex for capacity expansions without materially weakening the balance sheet.
Bears Say
Persistent Tariff Cost ExposureOngoing tariffs and related import costs are a sustained margin headwind; management models $60–65M of annual tariff spend and assumes no refunds. This structural cost pressure reduces margin upside and forces reliance on pricing or productivity to preserve long‑term profitability.
Earnings Volatility And Reporting InconsistenciesHistoric profit swings and inconsistent operating‑measure disclosures complicate forecasting and weaken confidence in margin sustainability. Such volatility makes medium-term planning, guidance credibility and comparability across quarters more difficult for investors and counterparties.
AST/service Softness & Inventory-driven Demand VariabilityDemand variability from med‑tech customers reducing inventories and episodic service softness creates structural cyclicality in parts of revenue. Service and consumable pull-through can be delayed, increasing short-to-medium term revenue and utilization volatility despite a stable installed base.
Steris News
2TG FAQ
What was Steris plc’s price range in the past 12 months?
Steris plc lowest stock price was €170.40 and its highest was €236.00 in the past 12 months.
What is Steris plc’s market cap?
Steris plc’s market cap is €19.29B.
When is Steris plc’s upcoming earnings report date?
Steris plc’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Steris plc’s earnings last quarter?
Steris plc released its earnings results on May 11, 2026. The company reported €2.453 earnings per share for the quarter, missing the consensus estimate of €2.47 by -€0.016.
Is Steris plc overvalued?
According to Wall Street analysts Steris plc’s price is currently Undervalued.
Does Steris plc pay dividends?
Steris plc does not currently pay dividends.
What is Steris plc’s EPS estimate?
Steris plc’s EPS estimate is 2.16.
How many shares outstanding does Steris plc have?
Steris plc has 97,457,680 shares outstanding.
What happened to Steris plc’s price movement after its last earnings report?
Steris plc reported an EPS of €2.453 in its last earnings report, missing expectations of €2.47. Following the earnings report the stock price went up 4.842%.
Which hedge fund is a major shareholder of Steris plc?
Currently, no hedge funds are holding shares in DE:2TG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Steris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€247.30 (22.31% Upside)
€247.30 (22.31% Upside)
Blogger Sentiment
Bullish
DE:2TG Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.22%
12-Months-Change
Fundamentals
Return on Equity
1.10%
Trailing 12-Months
Asset Growth
5.82%
Trailing 12-Months
Company Description
Steris plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
2TG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive financial and operational picture: STERIS delivered a record fiscal 2026 with double-digit adjusted EPS growth, exceptional free cash flow (~$983M), stronger leverage (gross debt/EBITDA ~1.2x), and multiple segment milestones (Healthcare, AST, Life Sciences). Management provided constructive FY2027 guidance (7–8% revenue growth, EPS up ~9–11%, modest margin expansion) while continuing shareholder returns (dividend increase, $1B buyback authorization) and strategic investments (manufacturing consolidation, tuck-in M&A, AI for service). Offsetting these positives are tangible near-term headwinds: tariff costs (~$60–65M annual spend with no refunds assumed), higher effective tax rates due to withholding and geographic mix, Q4 margin compression, AST service softness and inventory-led demand variability, and a forecasted reduction in free cash flow for FY2027. Overall, the highlights — record growth, strong cash generation, prudent capital allocation, and constructive guidance — outweigh the lowlights, which are manageable but notable operational and tax/tariff risks.View all DE:2TG earnings summaries2TG Revenue Breakdown
73.00% U.S.
25.39% Other locations
1.61% Ireland

2TG Stock 12 Month Forecast
Average Price Target
€247.30
▲(22.31% Upside)
Technical Analysis
Dexcom
―
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―









